Sangus Life Science Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 09-07-2024
- Paid Up Capital ₹ 0.10 M
as on 09-07-2024
- Company Age 7 Year, 7 Months
- Last Filing with ROC 31 Mar 2022
- Revenue 167.55%
(FY 2020)
- Profit 174.92%
(FY 2020)
- Ebitda 5689.18%
(FY 2020)
- Net Worth 78.25%
(FY 2020)
- Total Assets 27.05%
(FY 2020)
About Sangus Life Science
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Chandramani Jha and Shilpi Kumari serve as directors at the Company.
- CIN/LLPIN
U24239BR2017PTC034534
- Company No.
034534
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 May 2017
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Patna, Bihar, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Sangus Life Science Private Limited offer?
Sangus Life Science Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Antacid Drugs, Common Disease Medicines, Pharmaceutical Tablets, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Allopathic Cough Syrup, Respiratory System Drugs, Anti Asthma Drug.
Who are the key members and board of directors at Sangus Life Science?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chandramani Jha  | Director | 10-May-2017 | Current |
| Shilpi Kumari | Director | 10-May-2017 | Current |
Financial Performance of Sangus Life Science.
Sangus Life Science Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 167.55% increase. The company also saw a substantial improvement in profitability, with a 174.92% increase in profit. The company's net worth Soared by an impressive increase of 78.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sangus Life Science?
In 2019, Sangus Life Science had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sangus Life Science?
Unlock and access historical data on people associated with Sangus Life Science, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sangus Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sangus Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
